HIF-1α, pimonidazole, and iododeoxyuridine to estimate hypoxia and perfusion in human head-and-neck tumors

International Journal of Radiation Oncology Biology Physics

Volumn 54, Issue 5, 2002, Pages 1537-1549

  Janssen, Hilde L K ^a   Haustermans, Karin M G ^b   Sprong, Debbie ^a   Blommestijn, Gerard ^a   Hofland, Ingrid ^a   Hoebers, Frank J ^a   Blijweert, Elke ^b   Raleigh, James A ^c   Semenza, Gregg L ^d   Varia, Mahesh A ^c   Balm, Alfons J ^a   Van Velthuysen, Marie Louise F ^a   Delaere, Pierre ^b   Sciot, Raf ^b   Begg, Adrian C ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

HIF 1 ; Hypoxia; Pimonidazole; Predictive assay; Radiation therapy

Indexed keywords

BLOOD VESSELS; MICROELECTRODES; RADIOTHERAPY; SURGERY; TUMORS;

COLOCALIZATION;

ONCOLOGY;

IDOXURIDINE; KI 67 ANTIGEN; PIMONIDAZOLE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR HIF 1A; TUMOR MARKER; UNCLASSIFIED DRUG; HIF1A PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; NITROIMIDAZOLE DERIVATIVE; NUCLEIC ACID SYNTHESIS INHIBITOR;

ADULT; ARTICLE; BLOOD VESSEL; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; FEASIBILITY STUDY; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; IMMUNOHISTOCHEMISTRY; PERFUSION; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; STAINING; TUMOR BIOPSY; TUMOR VOLUME; ANOXIA; BIOSYNTHESIS; DIMERIZATION; DOSE RESPONSE; HEAD AND NECK TUMOR; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; TREATMENT OUTCOME;

ANOXIA; CARCINOMA, SQUAMOUS CELL; DIMERIZATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HEAD AND NECK NEOPLASMS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IDOXURIDINE; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; NEOVASCULARIZATION, PATHOLOGIC; NITROIMIDAZOLES; NUCLEIC ACID SYNTHESIS INHIBITORS; PERFUSION; TRANSCRIPTION FACTORS; TREATMENT OUTCOME;

EID: 0036883983     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(02)03935-4     Document Type: Article

References (55)

1. Hockel M., Schlenger K., Aral B., et al. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 56:1996;4509-4515.
2. Nordsmark M., Overgaard M., Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol. 41:1996;31-39.
3. Brizel D.M., Scully S.P., Harrelson J.M., et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res. 56:1996;941-943.
4. Brizel D.M., Sibley G.S., Prosnitz L.R., et al. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 38:1997;285-289.
5. Thomlinson R.H., Gray L.H. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer. 1955;539-549.
6. Brown J.M. Evidence for acutely hypoxic cells in mouse tumours and a possible mechanism of reoxygenation. Br J Radiol. 52:1979;650-656.
7. Dewhirst M.W., Kimura H., Rehmus S.W., et al. Microvascular studies on the origins of perfusion-limited hypoxia. Br J Cancer Suppl. 27:1996;S247-S251.
8. Kennedy A.S., Raleigh J.A., Perez G.M., et al. Proliferation and hypoxia in human squamous cell carcinoma of the cervix First report of combined immunohistochemical assays . Int J Radiat Oncol Biol Phys. 37:1997;897-905.
9. Raleigh J.A., Calkins-Adams D.P., Rinker L.H., et al. Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker. Cancer Res. 58:1998;3765-3768.
10. Varia M.A., Calkins-Adams D.P., Rinker L.H., et al. Pimonidazole A novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in cervical carcinoma . Gynecol Oncol. 71:1998;270-277.
11. Wijffels K.I., Kaanders J.H., Rijken P.F., et al. Vascular architecture and hypoxic profiles in human head and neck squamous cell carcinomas. Br J Cancer. 83:2000;674-683.
12. Evans S.M., Hahn S., Pook D.R., et al. Detection of hypoxia in human squamous cell carcinoma by EF5 binding. Cancer Res. 60:2000;2018-2024.
13. Raleigh J.A., Chou S.C., Arteel G.E., et al. Comparisons among pimonidazole binding, oxygen electrode measurements, and radiation response in C3H mouse tumors. Radiat Res. 151:1999;580-589.
14. Semenza G.L., Jiang B.H., Leung S.W., et al. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J Biol Chem. 271:1996;32529-32537.
15. Semenza G.L. Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol. 15:1999;551-578.
16. Jiang B.H., Rue E., Wang G.L., et al. Dimerization, DNA binding, and transactivation properties of hypoxia- inducible factor 1. J Biol Chem. 271:1996;17771-17778.
17. Maxwell P.H., Wiesener M.S., Chang G.W., et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 399:1999;271-275.
18. Wang G.L., Jiang B.H., Rue E.A., et al. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A. 92:1995;5510-5514.
19. Salceda S., Caro J. Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem. 272:1997;22642-22647.
20. Huang L.E., Gu J., Schau M., et al. Regulation of hypoxia-inducible factor 1alpha is mediated by an O2- dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A. 95:1998;7987-7992.
21. Kallio P.J., Wilson W.J., O'Brien S., et al. Regulation of the hypoxia-inducible transcription factor 1alpha by the ubiquitin-proteasome pathway. J Biol Chem. 274:1999;6519-6525.
22. Sutter C.H., Laughner E., Semenza G.L. Hypoxia-inducible factor 1alpha protein expression is controlled by oxygen-regulated ubiquitination that is disrupted by deletions and missense mutations. Proc Natl Acad Sci U S A. 97:2000;4748-4753.
23. Begg A.C., Hofland I., Van Der Pavert I., et al. Use of thymidine analogues to indicate vascular perfusion in tumours. Br J Cancer. 83:2000;899-905.
24. Zhong H., De Marzo A.M., Laughner E., et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 59:1999;5830-5835.
25. Haustermans K., Hofland I., Van de Pavert L., et al. Diffusion limited hypoxia estimated by vascular image analysis Comparison with pimonidazole staining in human tumors . Radiother Oncol. 55:2000;325-333.
26. Awwad H.K., el Naggar M., Mocktar N., et al. Intercapillary distance measurement as an indicator of hypoxia in carcinoma of the cervix uteri. Int J Radiat Oncol Biol Phys. 12:1986;1329-1333.
27. Delides G.S., Venizelos J., Revesz L. Vascularization and curability of stage III and IV nasopharyngeal tumors. J Cancer Res Clin Oncol. 114:1988;321-323.
28. Revesz L., Siracka E., Siracky J., et al. Variation of vascular density within and between tumors of the uterine cervix and its predictive value for radiotherapy. Int J Radiat Oncol Biol Phys. 16:1989;1161-1163.
29. Kolstad P. Intercapillary distance, oxygen tension and local recurrence in cervix cancer. Scand J Clin Lab Invest Suppl. 106:1968;145-157.
30. Lauk S., Skates S., Goodman M., et al. A morphometric study of the vascularity of oral squamous cell carcinomas and its relation to outcome of radiation therapy. Eur J Cancer Clin Oncol. 25:1989;1431-1440.
31. Raleigh J.A., Chou S.C., Arteel G.E., et al. Comparisons among pimonidazole binding, oxygen electrode measurements, and radiation response in C3H mouse tumors. Radiat Res. 151:1999;580-589.
32. Olive P.L., Durand R.E., Raleigh J.A., et al. Comparison between the comet assay and pimonidazole binding for measuring tumour hypoxia. Br J Cancer. 83:2000;1525-1531.
33. Raleigh J.A., Chou S.C., Calkins-Adams D.P., et al. A clinical study of hypoxia and metallothionein protein expression in squamous cell carcinomas. Clin Cancer Res. 6:2000;855-862.
34. Cline J.M., Thrall D.E., Rosner G.L., et al. Distribution of the hypoxia marker CCI-103F in canine tumors. Int J Radiat Oncol Biol Phys. 28:1994;921-933.
35. Rijken P.F., Bernsen H.J., Peters J.P., et al. Spatial relationship between hypoxia and the (perfused) vascular network in a human glioma xenograft A quantitative multi-parameter analysis . Int J Radiat Oncol Biol Phys. 48:2000;571-582.
36. Jiang B.H., Semenza G.L., Bauer C., et al. Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension. Am J Physiol. 271:1996;C1172-C1180.
37. Gross M.W., Karbach U., Groebe K., et al. Calibration of misonidazole labeling by simultaneous measurement of oxygen tension and labeling density in multicellular spheroids. Int J Cancer. 61:1995;567-573.
38. Arteel G.E., Thurman R.G., Yates J.M., et al. Evidence that hypoxia markers detect oxygen gradients in liver Pimonidazole and retrograde perfusion of rat liver . Br J Cancer. 72:1995;889-895.
39. Ravi R., Mookerjee B., Bhujwalla Z.M., et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia- inducible factor 1alpha. Genes Dev. 14:2000;34-44.
40. Chen C., Pore N., Behrooz A., et al. Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. J Biol Chem. 276:2001;9519-9525.
41. Zhong H., Chiles K., Feldser D., et al. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells Implications for tumor angiogenesis and therapeutics . Cancer Res. 60:2000;1541-1545.
42. Blancher C., Moore J., Robertson N., et al. Effect of ras and von Hippel-Lindau (VHL) gen mutations on hypoxia-inducible factor (HIF)-1 alpha, HIF-2 alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3-kinase/Akt signaling pathway. Cancer Res. 61:2001;7349-7355.
43. Jiang B.H., Agani F., Passaniti A., et al. V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1 Involvement of HIF-1 in tumor progression . Cancer Res. 57:1997;5328-5335.
44. Semenza G.L. HIF-1 and mechanisms of hypoxia sensing. Curr Opin Cell Biol. 13:2001;167-171.
45. Harris A.L. Hypoxia - a key regulatory factor in tumour growth. Nature Reviews Cancer. 2:2002;38-47.
46. Wiesener M.S., Munchenhagen P.M., Berger I., et al. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas. Cancer Res. 61:2001;5215-5222.
47. Kimura H., Weisz A., Kurashima Y., et al. Hypoxia response element of the human vascular endothelial growth factor gene mediates transcriptional regulation by nitric oxide Control of hypoxia-inducible factor-1 activity by nitric oxide . Blood. 95:2000;189-197.
48. Palmer L.A., Gaston B., Johns R.A. Normoxic stabilization of hypoxia-inducible factor-1 expression and activity Redox-dependent effect of nitrogen oxides . Mol Pharmacol. 58:2000;1197-1203.
49. Shih S.C., Claffey K.P. Role of AP-1 and HIF-1 transcription factors in TGF-beta activation of VEGF expression. Growth Factors. 19:2001;19-34.
50. Vukovic V., Haugland H.K., Nicklee T., et al. Hypoxia-inducible factor-1alpha is an intrinsic marker for hypoxia in cervical cancer xenografts. Cancer Res. 61:2001;7394-7398.
51. Olive P.L., Aquino-Parsons C., MacPhail S.H., et al. Carbonic anhydrase 9 as an endogenous marker for hypoxic cells in cervical cancer. Cancer Res. 61:2001;8924-8929.
52. Lando D., Peet D.J., Whelan D.A., et al. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science. 295:2002;858-861.
53. Bruick R.K., McKnight S.L. Transcription. Oxygen sensing gets a second wind. Science. 295:2002;807-808.
54. Aebersold D.M., Burri P., Beer K.T., et al. Expression of hypoxia-inducible factor-1alpha A novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer . Cancer Res. 61:2001;2911-2916.
55. Birner P., Gatterbauer B., Oberhuber G., et al. Expression of hypoxia-inducible factor-1 alpha in oligodendrogliomas Its impact on prognosis and on neoangiogenesis . Cancer. 92:2001;165-171.